If there is one thing that is certain in the pharmaceutical industry, the in-house counsels have their hands full. Regulations are changing all the time and they have to make sure they understand every nuance to ensure their companies remain compliant. At the 17th Annual Medicaid Drug Rebate Program Summit , in-house counsel from Bristol-Myers Squibb, Pfizer, and Eli Lilly will participate in an exclusive panel discussion on the issues they find the most challenging. They will discuss
• The challenges raised by CMS’ Proposed AMP Rule and any agency updates available
• Discreet legal issues affecting branded and generic products
• Best practices in dealing with GP-related compliance issues, including changes in laws, policy documentation, system issues and making GP more accessible to colleagues
It’s a session not to be missed, especially since they will be following sessions from the OIJ and DOJ on criminal and civil enforcement activities happening in the MDRP space. Come join us in Chicago September 10-12!